Enveric Biosciences Broadcasts Pricing of $5 Million Public Providing

Article content material

Article content material

Article content material

CAMBRIDGE, Mass. — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Firm”), a biotechnology firm devoted to the event of novel neuroplastogenic small-molecule therapeutics for the therapy of hysteria, melancholy, and habit problems, as we speak introduced the pricing of a public providing of an combination of 1,666,666 shares of its frequent inventory (or frequent inventory equivalents in lieu thereof), Sequence A warrants to buy as much as 1,666,666 shares of frequent inventory and Sequence B warrants to buy as much as 1,666,666 shares of frequent inventory, at a mixed public providing worth of $3.00 per share (or per frequent inventory equal in lieu thereof) and accompanying warrants. The warrants could have an train worth of $3.00 per share and can be exercisable instantly. The Sequence A warrants will expire 5 years from the date of issuance and the Sequence B warrants will expire eighteen months from the date of issuance. The closing of the providing is anticipated to happen on or about February 3, 2025, topic to the satisfaction of customary closing circumstances.

Article content material

H.C. Wainwright & Co. is appearing because the unique placement agent for the providing.

The gross proceeds from the providing, earlier than deducting the position agent’s charges and different providing bills payable by the Firm, are anticipated to be roughly $5 million. The Firm intends to make use of the web proceeds from this providing for product growth, working capital and common company functions.

The securities described above are being provided pursuant to a registration assertion on Type S-1 (File No. 333-284277), which was declared efficient by the Securities and Alternate Fee (the “SEC”) on January 30, 2025. The providing is being made solely via a prospectus forming a part of the efficient registration assertion referring to the providing. A preliminary prospectus referring to the providing has been filed with the SEC. Digital copies of the ultimate prospectus, when obtainable, could also be obtained on the SEC’s web site at http://www.sec.gov and might also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, third Ground, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press launch shall not represent a proposal to promote or a solicitation of a proposal to purchase any of the securities described herein, nor shall there be any sale of those securities in any state or different jurisdiction wherein such supply, solicitation or sale could be illegal previous to the registration or qualification underneath the securities legal guidelines of any such state or different jurisdiction.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology firm devoted to the event of novel neuroplastogenic small-molecule therapeutics for the therapy of melancholy, anxiousness, and habit problems. Leveraging its distinctive discovery and growth platform, the Psybrary™, which homes proprietary info on the use and growth of present and novel molecules for particular psychological well being indications, Enveric seeks to develop a sturdy mental property portfolio of novel drug candidates. Enveric’s lead molecule, EB-003, is a possible first-in-class neuroplastogen designed to advertise neuroplasticity, with out inducing hallucinations, in sufferers affected by difficult-to-address psychological well being problems. Enveric is concentrated on advancing EB-003 in direction of medical trials for the therapy of neuropsychiatric problems whereas out-licensing all different novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market methods for affected person care. Enveric is headquartered in Naples, FL with places of work in Cambridge, MA and Calgary, AB Canada. For extra info, please go to www.enveric.com.

Article content material

Ahead-Wanting Statements

This press launch incorporates forward-looking statements and forward-looking info inside the that means of relevant securities legal guidelines. These statements relate to future occasions or future efficiency. All statements aside from statements of historic truth could also be forward-looking statements or info. Typically, forward-looking statements and knowledge could also be recognized by way of forward-looking terminology similar to “plans,” “expects” or “doesn’t count on,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “doesn’t anticipate,” or “believes,” or variations of such phrases and phrases, or by way of phrases or phrases which state that sure actions, occasions or outcomes might, might, ought to, would, or may happen or be achieved. Ahead-looking statements might embody statements relating to beliefs, plans, expectations, or intentions relating to the longer term and are based mostly on the beliefs of administration in addition to assumptions made by and knowledge presently obtainable to administration, together with, however not restricted to, statements relating to the completion of the providing, the satisfaction of customary closing circumstances associated to the providing and the anticipated use of proceeds therefrom. Precise outcomes might differ materially from these contemplated by the forward-looking statements on account of sure elements, together with, however not restricted to, the flexibility of Enveric to: efficiently outlicense patented Psybrary™ drug candidates to third-party licensees; negotiate and finalize definitive agreements based mostly on any of its out-licensing time period sheets and for licensees to carry out pursuant to the phrases thereof; finalize and submit its IND submitting to the U.S. Meals and Drug Administration; perform profitable medical packages; obtain the worth creation contemplated by technical developments; keep away from delays in deliberate medical trials; set up that potential merchandise are efficacious or secure in preclinical or medical trials; set up or keep collaborations for the event of therapeutic candidates; acquire acceptable or crucial governmental approvals to market potential merchandise; acquire future funding for product growth and dealing capital on commercially cheap phrases; scale-up manufacture of product candidates; reply to adjustments within the measurement and nature of rivals; rent and retain key executives and scientists; safe and implement authorized rights associated to Enveric’s merchandise, together with patent safety; determine and pursue different routes to seize worth from its analysis and growth pipeline property; proceed as a going concern; and handle its future progress successfully.

View supply model on businesswire.com: https://www.businesswire.com/information/house/20250130844568/en/

Contacts

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

#distro

Article content material